LanDian Technology Group Co., Ltd. 2025 Annual Independent Director's Performance Report (Chen Geng)
To all shareholders and shareholder representatives:
As an independent director of LanDian Technology Group Co., Ltd. (hereinafter referred to as the "Company" or "LanDian Technology"), I have strictly followed the "Company Law," "Securities Law," "Shenzhen Stock Exchange Stock Listing Rules," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1 - Normative Operation of Main Board Listed Companies," "Management Measures for Independent Directors of Listed Companies," and other relevant laws, administrative regulations, normative documents, as well as the "Articles of Association," and the "Special Committee Work System for Independent Directors" and other relevant regulations. I have actively fulfilled my duties as an independent director, diligently reviewed all proposals submitted to the board of directors and special committees, exercised my independence and professionalism, and effectively protected the interests of the Company and all shareholders. The following is a report of my performance in 2025:
I. Basic Information
I, Chen Geng, born in September 1973, hold a Ph.D. in Economics, a postdoctoral degree in Business Administration, and am a professor of accounting and a doctoral supervisor. I am currently a professor at the School of Economics and Management, Chongqing University. I also serve as an independent director for LanDian Technology, Chongqing Laimi Pharmaceutical Co., Ltd., Fuan Pharmaceutical (Group) Co., Ltd., China Tianrui Automotive Interior Parts Co., Ltd. (listed in Hong Kong, stock code: 06162), and Jiutai Fund Management Co., Ltd.
I have served as an independent director of the Company since October 2020. Concurrently, I serve as the Chairman of the Audit Committee and a member of the Nomination, Remuneration and Assessment Committee of the Board of Directors. I do not hold any positions in the Company's principal shareholders, nor do I have any relationship of interest with the Company or its principal shareholders, or any other relationship that may hinder independent and objective judgment. There are no other circumstances that affect my independence as an independent director, which complies with the requirements of the "Management Measures for Independent Directors of Listed Companies," the "Shenzhen Stock Exchange Stock Listing Rules," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1 - Normative Operation of Main Board Listed Companies," and other relevant laws and regulations.
II. Performance in 2025
(I) Attendance at Board Meetings and Shareholder Meetings
During the reporting period, the Company held 11 board meetings, all of which I attended in person. I attended 9 meetings in person and 2 meetings via communication methods. There were no instances of proxy attendance or absence from board meetings. For proposals submitted to the board for deliberation, I carefully reviewed the meeting materials, communicated fully with other directors, the Company Secretary, and other relevant personnel to understand the relevant information of the proposals, offered reasonable suggestions, and exercised my voting rights prudently. I voted in favor of all proposals deliberated by the board during the reporting period, with no dissenting or abstention votes.
During the reporting period, the Company held 3 shareholder meetings, all of which I attended.
(II) Attendance at Board Special Committees and Independent Director Meetings
During the reporting period, I served as the Chairman of the Audit Committee and a member of the Nomination, Remuneration and Assessment Committee of the Board of Directors.